Últimas noticias sobre Waters (NYSE:WAT) Bolsa

Waters

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Waters Corp

WATERCO LTD by WATERCO LTD.

Energous Corp

WATERMARK LODGING TRUST A by Watermark Lodging Trust Inc.

WATCHES OF SWITZERLAND G by Watches of Switzerland Group PLC

Watches of Switzerland Group PLC

WATER INTELLIGENCE PLC by Water Intelligence PLC

Water Intelligence PLC

WATER OASIS GROUP LTD by Water Oasis Group Ltd.

Water Oasis Group Ltd

WATER TECH INTL by Water Technologies International,Inc.

Water Technologies International Inc

WATER WAYS TECHS INC by WATER WAYS TECHNOLOGIES INC

Water Ways Technologies Inc

WATERPURE INTL INC by WaterPure International, Inc.

WaterPure International Inc

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Waterdrop Inc

Waterloo Brewing Ltd

Waterstone Financial, Inc. - Common Stock

Waterstone Financial Inc

Waton Financial Limited - Ordinary Shares

Waton Financial Ltd

Watsco Inc

Watts Co Ltd

Watts Water Technologies, Inc. Class A Common Stock

Watts Water Technologies Inc

These ten large-cap stocks were the worst performers last week. Are they a&nbsp;<a target="_blank" href="https://www.benzinga.com/trading-ideas" rel="noreferrer noopener">part of your portfolio</a>?
<ol class="wp-block-list">
<li>Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) shares decreased 17.96% this week after the company lowered its <a href="https://www.benzinga.com/markets/earnings/25/07/46468951/elevance-health-hit-by-medicaid-troubles-trims-outlook" target="_blank" rel="noreferrer noopener">fiscal year 2025 adjusted earnings guidance</a>. The company missed earnings in the second quarter. Also, multiple analysts lowered their <a href="https://www.benzinga.com/quote/ELV/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) fell 9.50% this week  after the company agreed to combine Becton, Dickinson and Company&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) Biosciences &amp; Diagnostic Solutions <a href="https://www.benzinga.com/m-a/25/07/46389674/bectons-biosciences-and-diagnostics-arm-slated-to-join-waters-in-17-5-billion-merger\" target="_blank" rel="noreferrer noopener">business with Waters</a>. Also, Wells Fargo downgraded the stock from Overweight to Equal-Weight and lowered its <a href="https://www.benzinga.com/quote/WAT/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $420 to $330</a>.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) slumped 13.19% this week.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares fell 10.49% this week amid a selloff in the sector following Elevance&#8217;s recent soft guidance and broader concerns <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46474212/centene-stock-hit-a-new-52-week-low-today-whats-going-on" target="_blank" rel="noreferrer noopener">over rising medical costs</a>.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) shares slumped 11.27% this week. The company and ENI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/E#NYSE">E</a>) of Italy announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 2 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from CP2 LNG, Venture Global&#8217;s third project, for 20 years.&nbsp;</li>
<li>Schlumberger N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) stock slumped 8.87% this week after the company reported second-quarter financial results, issued expectations for flat-to-low single-digit revenue growth in the second half of 2025, and stated that tariffs will cost <a href="https://www.benzinga.com/markets/earnings/25/07/46492669/slb-trims-2025-capital-spending-prioritizing-efficiency-post-championx-deal" target="_blank" rel="noreferrer noopener">between 20-to-40 basis points of margin</a>. Additionally, Piper Sandler lowered its price forecast <a href="https://www.benzinga.com/quote/slb/analyst-ratings" target="_blank" rel="noreferrer noopener">from $44 to $42</a>.</li>
<li>Penske Automotive Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAG#NYSE">PAG</a>) shares decreased 9.79% this week after JP Morgan lowered the price target from $160 to $155 <a href="https://www.benzinga.com/quote/PAG/analyst-ratings" target="_blank" rel="noreferrer noopener">while maintaining an Underweight rating</a>.</li>
<li>Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) stock declined 7.72% this week after the firm announced it would be pulling the plug on the development of its Hydrogen fuel cell technology, citing no potential in the <a href="https://www.benzinga.com/markets/tech/25/07/46437558/stellantis-abandons-hydrogen-vehicle-plans-citing-weak-infrastructure-and-incentives-report" target="_blank" rel="noreferrer noopener">sector in the mid-term future</a>.</li>
<li>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shares fell 7.39% this week after the company said it <a href="https://www.benzinga.com/markets/equities/25/07/46438500/asml-stock-plunges-nearly-8-in-wednesday-pre-market-whats-going-on">cannot confirm 2026 growth</a> outlook after strong second quarter earnings.</li>
<li>TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) stock fell 7.25% this week after BTIG analyst Greg Lewis downgraded the <a href="https://www.benzinga.com/quote/fti/analyst-ratings" target="_blank" rel="noreferrer noopener">company from Buy to Neutral</a>.</li>
</ol>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46507927/blackstone-backs-out-of-tiktok-us-deal-as-trump-deadline-looms-china-opposition-mounts-report" target="_blank" rel="noreferrer noopener">Blackstone Backs Out Of TikTok US Deal As Trump Deadline Looms, China Opposition Mounts: Report</a></li>
</ul>
Photo courtesy Skorzewiak via Shutterstock

Large Cap

News

Movers

ASML

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

NTRA

STLA

Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?

Baird analyst Catherine Ramsey maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Outperform and lowers the price target from $374 to $352.

Price Target

Analyst Ratings

Baird Maintains Outperform on Waters, Lowers Price Target to $352

WIIM

Waters shares are trading lower after Wells Fargo downgraded the stock from Overweight to Equal-Weight and lowered its price target from $420 to $330.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Morgan Stanley raised Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) price target from $43 to $110. Morgan Stanley analyst Michael Cyprys maintained an Equal-Weight rating. Robinhood shares closed at $99.96 on Monday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays cut the price target for Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) from $180 to $145. Barclays analyst Jiong Shao maintained an Overweight rating. Alibaba shares closed at $108.22 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/BABA/analyst-ratings">view this stock</a>.</li>
<li>Wells Fargo cut Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) price target from $420 to $330. Wells Fargo analyst Brandon Couillard downgraded the stock from Overweight to Equal-Weight. Waters shares closed at $304.18 on Monday. <a href="https://www.benzinga.com/quote/WAT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc boosted the price target for Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) from $105 to $115. Keybanc analyst Steve Barger maintained an Overweight rating. Lam Research shares closed at $99.62 on Monday. <a href="https://www.benzinga.com/quote/lrcx/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS cut the price target for Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) from $15 to $11. UBS analyst Jonathan Yong downgraded the stock from Neutral to Sell. Oscar Health shares closed at $15.08 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/oscr/analyst-ratings">view this stock</a>.</li>
<li>JMP Securities raised DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) price target from $235 to $250. JMP Securities analyst Andrew Boone maintained a Market Outperform rating. DoorDash shares settled at $242.85 on Monday. <a href="https://www.benzinga.com/quote/dash/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities increased Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) price target from $765 to $775. B of A Securities analyst Justin Post maintained a Buy rating. Meta shares closed at $720.92 on Monday. <a href="https://www.benzinga.com/quote/meta/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stephens &amp; Co. raised Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) price target from $40 to $45. Stephens &amp; Co. analyst Tommy Moll maintained an Equal-Weight rating. Fastenal shares closed at $45.07 on Monday.  <a href="https://www.benzinga.com/quote/fast/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised the price target for California Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) from $60 to $63. JP Morgan analyst Zach Parham upgraded the stock from Neutral to Overweight. California Resources shares settled at $47.60 on Monday. <a href="https://www.benzinga.com/quote/crc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) price target from $127 to $137. Morgan Stanley analyst David Lewis maintained an Equal-Weight rating. Abbott shares closed at $132.03 on Monday. <a href="https://www.benzinga.com/quote/abt/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying META stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15090858/image-179-1024x589.png" alt="" class="wp-image-985970" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15090858/image-179-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15090858/image-179-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15090858/image-179-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15090858/image-179.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday">JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

BABA

DASH

FAST

HOOD

LRCX

OSCR

Meta To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday

During the last three months, 5 analysts shared their evaluations of Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $358.8, with a high estimate of $375.00 and a low estimate of $330.00. A 8.8% drop is evident in the current average compared to the previous average price target of $393.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1752584466_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Waters is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$330.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$375.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$374.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$355.00</td>
<td>$407.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Waters. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Waters's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Waters's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Waters analyst ratings.</a>
<h2>Get to Know Waters Better</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions.
<h3>Waters: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Waters's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.9% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 18.34%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Waters's ROE stands out, surpassing industry averages. With an impressive ROE of 6.4%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Waters's ROA excels beyond industry benchmarks, reaching 2.65%. This signifies efficient management of assets and strong financial health.
Debt Management: Waters's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.78.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss Waters Stock

Wells Fargo analyst Brandon Couillard downgrades Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) from Overweight to Equal-Weight and lowers the price target from $420 to $330.

Downgrades

Wells Fargo Downgrades Waters to Equal-Weight, Lowers Price Target to $330

General

Waters Corp Says Merger Agreement Requires Co To Pay BD Termination Fee Of $733M If Agreement Is Terminated Under Certain Circumstances

Waters shares are trading lower after the company agreed to combine Becton, Dickinson's Biosciences & Diagnostic Solutions business with Waters.

Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)&nbsp;has agreed to combine its Biosciences &amp; Diagnostic Solutions business with Waters Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>).
The agreement is structured as a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion. The transaction is expected to close around the end of the first quarter of calendar year 2026.
<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Biosciences segment</a> offers immunology and cancer research solutions and related clinical diagnostics, including flow cytometry instruments, reagents, and multiomics tools.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/05/45179007/becton-dickinson-vitals-drop-analysts-have-been-wrong-on-this-med-tech-stock-for-years" target="_blank" rel="noreferrer noopener">Becton Dickinson Vitals Drop: Analysts &#8216;Have Been Wrong&#8217; On This Med Tech Stock For Years</a>
Diagnostic Solutions offers microbiology and infectious disease diagnostics, including molecular diagnostics, cervical cancer screening, microbiology automation, and point-of-care offerings.
For calendar year 2025, BD&#8217;s Biosciences &amp; Diagnostic Solutions business is expected to generate revenue of approximately&nbsp;$3.4 billion&nbsp;and adjusted EBITDA of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46387499/waters-and-bds-biosciences-diagnostic-solutions-business-to-combine-creating-a-life-science-and-di" rel="noreferrer noopener">approximately&nbsp;$925 million</a>.
<h2 class="wp-block-heading">Financial Benefits</h2>
The transaction is expected to create approximately&nbsp;$200 million&nbsp;of cost synergies by year three post-closing, and approximately&nbsp;$290 million&nbsp;of revenue synergies by year five, resulting in approximately&nbsp;$345 million&nbsp;of annualized EBITDA synergies by 2030.
Cost synergies are expected to be driven primarily by manufacturing, supply chain, and SG&amp;A optimization while maintaining a strong commitment to R&amp;D and commercial investments.
Revenue synergies are expected from commercial excellence, accelerating expansion into high-growth adjacencies, and realizing cross-selling opportunities.
The combined company is expected to generate pro forma revenue of approximately&nbsp;$6.5 billion&nbsp;and approximately&nbsp;$2.0 billion&nbsp;in pro forma adjusted EBITDA for calendar year 2025.
On a pro forma basis, the combination is expected to deliver mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth on an annualized basis between 2025 and 2030.
By 2030, the pro forma combined company is expected to have an industry-leading financial outlook with approximately&nbsp;$9 billion&nbsp;in revenue,&nbsp;$3.3 billion&nbsp;in adjusted EBITDA, and an adjusted operating margin of 32%.
The transaction is expected to be accretive to adjusted EPS in the first year post-closing.
Commenting on the transaction, Flemming Ornskov, Chairman, Waters, said, &#8220;This transaction marks a pivotal milestone in Waters&#8217; transformation journey as we embark on a new chapter of growth and value creation. As the Board of Directors evaluated this opportunity throughout the process, it became evident that combining with BD&#8217;s Biosciences &amp; Diagnostic Solutions business is an excellent strategic fit with complementary strengths. We are confident that this combination will accelerate our strategy in multiple high-growth markets and deliver substantial near- and long-term value to our shareholders.&#8221;
BD&#8217;s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters shareholders are expected to own approximately 60.8%. BD will also receive a cash distribution of approximately $4 billion before completion of the combination.
Waters is expected to assume approximately&nbsp;$4 billion&nbsp;of incremental debt, resulting in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing.
Price Action: WAT stock was down 5.07% at $335, and BDX stock was down 0.84% at $174.50 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46386582/elon-musk-wants-tesla-to-invest-in-xai-but-its-up-to-shareholders-this-analyst-says-grok-is-worth-the-bet" target="_blank" rel="noreferrer noopener">Elon Musk Wants Tesla To Invest In xAI, But It&#8217;s Up To Shareholders: This Analyst Says Grok Is Worth The Bet</a></li>
</ul>
Photo via Shutterstock

Health Care

Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Merger

<ul>
<li>The companies expect that the transaction will create substantial shareholder value by:</li>
<li>Bringing together complementary technologies to serve high-volume testing in attractive and regulated end-markets: The combined company will have best-in-class liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions, doubling Waters' total addressable market to approximately $40 billion.</li>
<li>Increasing annual recurring revenue in high-quality applications: Over 70% of the combined company's revenue is expected to be recurring annually and over half of instrument revenue is expected to be recurring within a typical five- to ten-year replacement cycle.</li>
<li>Accelerating Waters' expansion into multiple high-growth adjacent end-markets:
<ul>
<li>The&nbsp;bioseparations portfolio will expand by combining Waters' chemistry expertise and BD's biologics expertise to unlock new ways to separate large molecules and to drive growth in biologics and novel modalities with next-generation consumables.</li>
<li>In&nbsp;bioanalytical characterization, Waters' expertise in downstream high-volume applications and its established Empower&#x2122; informatics platform are well-positioned to deploy BD's flow cytometry and PCR technologies into large molecule QA/QC.</li>
<li>BD's regulatory expertise and established presence in clinical and diagnostic settings is expected to drive enhanced market access, improved service support, accelerated menu expansion, and automation for multiplex diagnostics using LC-MS technologies from Waters. Applying Waters' proven execution model to unlock the full potential of&nbsp;BD's Biosciences &amp; Diagnostic Solutions business:&nbsp;Waters will systematize execution across instrument replacement, service plan attachment, e-commerce adoption, and new product launches. &nbsp;</li>
</ul>
</li>
<li>Delivering substantial cost and revenue synergies:&nbsp;The transaction is expected to create approximately $200 million of cost synergies by year three post-closing, and approximately $290 million of revenue synergies by year five, resulting in approximately $345 million of annualized EBITDA synergies by 2030.
<ul>
<li>Cost synergies are expected to be driven primarily by optimization in manufacturing, supply chain, and SG&amp;A, while maintaining a strong commitment to R&amp;D and commercial investments.</li>
<li>Revenue synergies are expected to be derived from commercial excellence, accelerating expansion into high-growth adjacencies, and realizing cross-selling opportunities. &nbsp;</li>
</ul>
</li>
<li>Providing an industry-leading pro forma growth outlook with rapid adjusted EPS accretion:&nbsp;The combined company is expected to generate pro forma revenue of approximately $6.5 billion and approximately $2.0 billion in pro forma adjusted EBITDA for calendar year 2025. On a pro forma basis, the combination is expected to deliver mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth on an annualized basis between 2025 and 2030. By 2030, the pro forma combined company is expected to have an industry-leading financial outlook with approximately $9 billion in revenue, $3.3 billion in adjusted EBITDA, and an adjusted operating margin of 32%. The transaction is expected to be accretive to adjusted EPS in the first year post-closing.</li>
</ul>

Waters And Becton, Dickinson Agreed To Combine BD's Biosciences & Diagnostic Solutions Business With Waters. The Agreement Is Structured As A Tax-efficient Reverse Morris Trust Transaction Valued At Approximately $17.5B

Across the recent three months, 6 analysts have shared their insights on Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $379.0, with a high estimate of $460.00 and a low estimate of $350.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.67%. 
<img src="https://www.benzinga.com/files/images/story/2025/1750960880_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Waters among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$375.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$374.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$355.00</td>
<td>$407.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Paul Knight</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$460.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Waters. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Waters's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Waters analyst ratings.</a>
<h2>Unveiling the Story Behind Waters</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions.
<h3>Waters's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Waters displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 3.9%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Waters's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.34% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Waters's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.4% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.65%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.78.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 6 Analyst Projections For Waters

B of A Securities analyst Derik De Bruin maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and raises the price target from $370 to $375.

B of A Securities Maintains Neutral on Waters, Raises Price Target to $375

Waters Acquires Halo Labs, Terms Not Disclosed

12 analysts have expressed a variety of opinions on Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $400.08, a high estimate of $460.00, and a low estimate of $350.00. Observing a 0.18% increase, the current average has risen from the previous average price target of $399.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1746648019_0_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Waters. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$374.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$355.00</td>
<td>$407.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Paul Knight</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$460.00</td>
<td>-</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$407.00</td>
<td>$396.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$390.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$450.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$410.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$410.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$415.00</td>
<td>$360.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Waters. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Waters's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Waters's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Waters analyst ratings.</a>
<h2>Delving into Waters's Background</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>Breaking Down Waters's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Waters's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 6.5%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.51%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Waters's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.49% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Waters's ROA excels beyond industry benchmarks, reaching 5.11%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.93, Waters adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Waters's Future

Baird analyst Catherine Ramsey maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Outperform and raises the price target from $355 to $374.

Baird Maintains Outperform on Waters, Raises Price Target to $374

UBS analyst Elizabeth Garcia maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and lowers the price target from $415 to $360.

UBS Maintains Neutral on Waters, Lowers Price Target to $360

Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of <a href="https://www.benzinga.com/topic/federal-reserve">Wednesday&#8217;s Federal Reserve meeting.</a>
In a meeting with Canadian Prime Minister Mark Carney, President Donald Trump suggested the U.S. may soon begin renegotiating the USMCA. He noted that China is eager to negotiate due to its struggling economy, driven by a lack of U.S. trade, but emphasized the talks would take place &#8220;at the right time.&#8221;
Trump kept his trade stance unclear, suggesting that while some agreements may be signed, there is no obligation to finalize any, and dismissed repeated questions about the number of deals in progress.
The S&amp;P 500 dipped 30 points, or 0.6%, to 5,610, on track for its second consecutive negative session after nine straight gains. The Nasdaq 100 dropped 0.8%, while the Russell 2000 slipped 1%.
Ten of the 11 S&amp;P 500 sectors were in the red, with utilities as the only sector in the green. The U.S. dollar fell, extending its losses for a third straight session.
Commodities saw a broad rally, with oil prices surging 3.6%, pushing WTI above $59, following <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45224883/oil-soars-above-59-as-middle-east-airstrikes-jolt-markets">Israeli airstrikes in Yemen</a>. Gold also rallied, climbing 2.4% to above $3,400 per ounce amid heightened geopolitical tensions.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reversed Monday's gains, slipping 0.4% to $94,375.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,614.65</td>
<td>-0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,905.06</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,796.10</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,983.93</td>
<td colspan="2">-1.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.7% to $559.24.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.8% to $409.01.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.9% to $481.23.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) tumbled 1.1% to $196.68.</li>
<li>The&nbsp;Utilities&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 1.2%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 2.4%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks reacting to earnings reports included: 
<ul>
<li>Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) up 2.70%</li>
<li>The Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) down 2.31%</li>
<li>Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) down 9.95%</li>
<li>Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) down 13.9%</li>
<li>Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) down 0.53%</li>
<li>Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) down 0.68%</li>
<li>The Williams Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) down 5.19%</li>
<li>Celanese Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) up 9.14%</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) down 7.37%</li>
<li>Lattice Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) down 13.6%</li>
<li>Mattel Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) up 3.61%</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) down 13.6%</li>
<li>Duke Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) up 2.24%</li>
<li>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) up 10.94%</li>
<li>TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) down 5.67%</li>
<li>Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) up 1.26%</li>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) down 3.32%</li>
<li>American Electric Power Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) up 0.52%</li>
<li>Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) up 0.37%</li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) down 2.88%</li>
<li>WEC Energy Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) up 0.77%</li>
<li>Gartner, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) up 1.14%</li>
<li>IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) down 1.32%</li>
<li>Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) up 2.02%</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) down 4.43%</li>
<li>Leidos Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) up 4.11%</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) down 1.43%</li>
<li>GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) down 3.57%</li>
<li>Expeditors International of Washington, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>) down 3.67%</li>
<li>Ball Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) up 0.55%</li>
<li>Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) down 5.56%</li>
</ul>
Stocks slated to report earnings after the close include: Assurant Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>), Arista Networks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>), Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), International Flavors &amp; Fragrances Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>), Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Mosaic Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>), Corpay Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>), Wynn Resorts Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>), Jack Henry &amp; Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>), Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>), Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), Coty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) and Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>).
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45205780/sp-500-stocks-that-defy-sell-in-may-myth-5-companies-with-strong-historical-gains">S&amp;P 500 Stocks That Defy &#8216;Sell In May&#8217; Myth: 5 Companies With Strong Historical Gains</a></li>
</ul>
Photo: Gumbariya via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Government

Macro Economic Events

Mid Cap

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Small Cap

Global

Econ #s

Economics

ETFs

$BTC

ANET

BALL

COTY

CPAY

CTRA

SPDR Dow Jones Industrial Average ETF Trust

EXPD

FANG

JKHY

LDOS

LSCC

PLTR

RIVN

SMCI

VRTX

WYNN

Select Sector SPDR-Consumer Discretionary

Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) raises FY2025 Adj EPS guidance from $12.70-$13.00 to $12.75-$13.05 vs $12.86 analyst estimate. Raises FY2025 sales outlook from $3.03 billion-$3.11 billion to $3.11 billion-$3.17 billion vs $3.08 billion estimate.

Guidance

Waters Raises FY2025 Adj EPS Guidance from $12.70-$13.00 to $12.75-$13.05 vs $12.86 Est; Raises FY2025 Sales Guidance from $3.03B-$3.11B to $3.11B-$3.17B vs $3.08B Est

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) is looking for Q2 Adj EPS of $2.88-$2.98 vs $2.93 analyst estimate. sees sales of $743.955 million-$758.126 million vs $740.35 million analyst estimate.

Waters Sees Q2 Adj EPS $2.88-$2.98 vs $2.93 Est; Sees Sales $743.955M-$758.126M vs $740.35M Est

Waters Assimilates Multi-Angle Light Scattering Detectors With Empower Software For Improved Biologics Quality Control

Press Releases

Waters Corporation Schedules Second Quarter 2025 Earnings Conference Call

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

WAT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Waters Corporation Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGRM, WAT, SONN on Behalf of Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGRM, WAT, VBTX on Behalf of Shareholders

WATERS CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WAT, VBTX, MGRM on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ONCO, WAT, XAGE on Behalf of Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: KLG, CAPN, OLO, and WAT

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRGX, WAT, CORZ on Behalf of Shareholders

CAPN

CORZ

CRGX

MGRM

ONCO

SONN

VBTX

XAGE

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Waters

Noticias

Últimas noticias sobre Waters (NYSE:WAT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL